Next Science (ASX:NXS) ROCE % : -133.34% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Next Science ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Next Science's annualized ROCE % for the quarter that ended in Dec. 2023 was -133.34%.

Next Science ROCE % Historical Data

The historical data trend for Next Science's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Next Science ROCE % Chart

Next Science Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-47.05

-57.81

-65.88

-127.39

-130.34

Next Science Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial					-86.75	-92.49	-110.24	-185.26	-133.34

Next Science ROCE % Calculation

Next Science's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-23.209	/	( ( (18.466 - 3.864)	+	(26.743 - 5.732) )	/ 2 )
	=	-23.209	/	( (14.602	+	21.011)	/ 2 )
	=	-23.209	/	17.8065
	=	-130.34 %

Next Science's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-21.884	/	( ( (17.709 - 5.896)	+	(26.743 - 5.732) )	/ 2 )
	=	-21.884	/	( ( 11.813	+	21.011 )	/ 2 )
	=	-21.884	/	16.412
	=	-133.34 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Next Science (ASX:NXS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Next Science ROCE % Related Terms

Thank you for viewing the detailed overview of Next Science's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Next Science (ASX:NXS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (ASX:NXS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

NXSCF:USA

Address

821 Pacific Highway, Suite 1902, Level 19, Tower A, The Zenith Building, Chatswood, NSW, AUS, 2067

Website

https://www.nextscience.com

Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from the U.S. and Australia, of which prime revenue is derived from the U.S.

Next Science (ASX:NXS) Headlines

No Headlines